BIOS is developing a full-stack neural interface platform, that is optimised to decode and encode the signals from the brain to the body, to treat chronic health conditions. BIOS is unlocking the potential of the nervous system in treating chronic disease by using AI-powered neural interfaces that can automatically read and write neural signals. Our implanted neural interface connects directly with the nerves to isolate the signals that travel between the brain and the body.
For a person with a severe chronic condition, this means that they can stop worrying about their chronic disease. Their condition will be managed via the nervous system directly by AI, giving personalised and accurate treatments, so that the burden of pills and doctors visits become a second resort rather than a daily reality. Neural interfaces are a powerful new technology that can give us new levels of control over our bodies and lives like never before. BIOS is positioned to provide the neural interface platform on which a new generation of treatments can be built, that can enable millions of people suffering from chronic diseases to improve their quality of life.
Total Funding: $5,638,060
Funding Stage: Seed
Business Stage: Scaling Up
Market: B2B
Company Size: 26 to 50
Founded: 2015